» Advanced search
Only first 10,000 results will be saved in the file.
No item is selected. Use checkboxes to select search results.
Displaying 1-1 of 1 results.
{{ selectedCountPage }} items selected on this page, {{ selectedCountPage }} item selected on this page, {{ selectedCountTotal }} item in total {{ selectedCountTotal }} items in total
Study aim: Determination of the effect of curcumin-piperine supplementation on disease duration, severity, and clinical signs and inflammatory factors in patients with coronavirus (COVID-19): A randomized, double-blind, placebo-controlled clinical trial study Design: This is a randomized, placebo-controlled, double-blind parallel-group clinical trial. One hundred participants will be randomly allocated to receive curcumin-piperine supplement per day (25 inpatients and 25 outpatients) or placebo (25 inpatients and 25 outpatients). Settings and conduct: In this study, patients with coronavirus will be recruited from hospitals of Isfahan University of Medical Sciences. Subjects will be stratified according to gender. Random assignment will be done by the use of a table of random numbers. The enrolling participants, and assigning participants to the groups will be carried out by a relevant specialist.The curcumin-piperine supplement and its placebos will be packed in similar boxes, and the researcher and the patients will not be aware of the content of the pack until the end of the study. Participants/Inclusion and exclusion criteria: Inclusion criteria: Tendency to participate in the study; People aged 18-65 years; Diagnosis of Covid-19 based on the PCR test. Exclusion criteria: Age less than 20 and more than 75 years; Taking warfarin; Sensitivity to herbal products such as turmeric and pepper Intervention groups: Individuals will be randomly assigned to two groups to receive the curcumin-piperine supplement (1000 mg/day of curcumin and 10 mg/day of piperine) or placebo (1010 mg of maltodextrin) for 2 weeks. Main outcome variables: CT of the chest, body temperature, length of hospital stay, hs-CRP, ESR, ALT, AST, LDH, BUN, creatinine, CBC, blood oxidative stress indices ( SOD, MDA, TAC), Albumin, Severity of the disease, severity and number of coughs
IRCTID: IRCT20121216011763N46
  1. Evaluation of the effect of curcumin-piperine supplementation in patients with coronavirus admitted to the intensive care unit (ICU): a double-blind clinical trial studyCommunity Verified icon
  2. The effect of curcumin-piperine supplementation on inflammatory factors and clinical signs in patients with rheumatoid arthritis: a double-blind clinical trial study
  3. The effect of Curcumin-Piperine supplementation on cardiometabolic factors, hepatic steatosis and fibrosis of fibroscan results and liver function in patients with non-alcoholic fatty liver disease: a randomized double-blind clinical trial
  4. Evaluation of the effectiveness of curcumin-piperine supplementation on inflammatory factors, cardiac biomarkers, atrial fibrillation and clinical outcomes after coronary artery bypass graft surgery (CABG): A randomized double-blind, placebo-controlled, dose–response study
  5. A comparison of Elderberry (Sambucus nigra) extract syrup and placebo against COVID-19 symptoms in outpatients and home quarantined patients: A randomized double-blind clinical trial
  6. The effect of curcumin supplementaion on clinical symptoms , acute phase reactants and inflamatory cytokines in patients with covid-19 hospitalization
  7. Evaluation of the effect of curcumin-piperine supplement administration on the severity of injury and function in patients with acute ischemic stroke
  8. The effects of curcumin plus piperine supplementation on cardiometabolic risk factors and fibroscan findings in patients with moderate-to-high hepatic steatosis : a randomized double blind placebo-controlled trial
  9. Evaluation of the effect of trans sodium crocetinate in respiratory distress caused by COVID-19
  10. The effect of chitosan supplementation on clinical symptoms in patients with COVID-19